KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $42.4 million.

  • Novavax's Cash from Financing Activities rose 4385463.92% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 9151.5%. This contributed to the annual value of $260.6 million for FY2024, which is 573481.86% up from last year.
  • Per Novavax's latest filing, its Cash from Financing Activities stood at $42.4 million for Q3 2025, which was up 4385463.92% from -$1.0 million recorded in Q2 2025.
  • Novavax's 5-year Cash from Financing Activities high stood at $577.0 million for Q1 2021, and its period low was -$354.4 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $4.7 million (2022), whereas its average is $57.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 32167.39% in 2023, then soared by 4385463.92% in 2025.
  • Novavax's Cash from Financing Activities (Quarter) stood at -$60.7 million in 2021, then surged by 415.33% to $191.4 million in 2022, then crashed by 47.56% to $100.4 million in 2023, then tumbled by 103.41% to -$3.4 million in 2024, then skyrocketed by 1340.27% to $42.4 million in 2025.
  • Its Cash from Financing Activities was $42.4 million in Q3 2025, compared to -$1.0 million in Q2 2025 and -$7.1 million in Q1 2025.